Clin Endocrinol (Oxf) by Shroff, M.R. et al.
Mid-pregnancy maternal leptin levels, birthweight for gestational
age and preterm delivery
M.R. Shroffa, C. Holzmanb, Y. Tianb, R. W. Evansc, and A. Sikorskiid
aMichigan Public Health Institute, Okemos, MI 48864
bDepartment of Epidemiology, Michigan State University, East Lansing, MI 48824
cDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261
dDepartment of Statistics and Probability, Michigan State University, East Lansing, MI 48824
Summary
Objective—Maternal blood leptin levels are positively associated with adiposity. Recent studies
suggest that leptin is also abundantly produced by the placenta and may function as a regulator of
fetal growth. Our goal was to examine mid-pregnancy levels of leptin in maternal blood in relation
to birthweight for gestational age (BW/GA) and timing of delivery after accounting for maternal
pre-pregnancy body mass index (prepreg-BMI) and pregnancy complications.
Patients—Data were from 1,304 sub-cohort mother/infant pairs who participated in the
Pregnancy Outcomes and Community Health (POUCH) Study (1998–2004).
Measurements—Leptin levels, measured at 16–27 weeks’ gestation, were log-transformed.
Geometric mean (GMean) leptin levels were estimated by weighted linear regression with
gestational age at blood draw as a covariate. GMean was re-transformed to the original scale for
reporting.
Results—Using the GMeans leptin in mothers of term appropriate-for-gestational age (AGA)
neonates as the referent (25.2 μg/L), we observed lower levels in mothers of preterm AGA (21.9
μg/L), term small-for-gestational age (SGA) (20.3 μg/L), and preterm SGA neonates (21.7 μg/L).
Results were largely unchanged after adjustment for prepreg-BMI. Leptin levels were higher in
mothers who delivered large-for-gestational age (LGA) neonates, both preterm (33.6 μg/L) and
term (29.1 μg/L), but the GMeans were markedly attenuated after adjustment for prepreg-BMI.
Conclusion—The association between BW/GA and maternal leptin levels after adjustment for
prepreg-BMI may represent: 1) a residual effect of maternal adiposity that is not fully captured by
BMI; and/or 2) variation in placental leptin levels entering the maternal circulation. In conclusion,
mid-pregnancy maternal blood leptin levels may be an early indicator of fetal growth status.
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Introduction
Leptin, widely known as an adipose-tissue secreted protein, is involved in many metabolic
and hormonal regulation pathways in humans (1, 2). Under normal physiological conditions,
leptin primarily regulates energy balance and is produced predominantly by adipose tissues
(3). During pregnancy, leptin is abundantly produced by the placenta with 95% being
secreted into the maternal circulation. (4, 5) Leptin levels rise substantially during
pregnancy with low levels seen in the first trimester, a peak in the second, and a plateau in
the third trimester. (6) Higher levels have been observed with increasing maternal adiposity.
(7, 8) Studies suggest that leptin affects physiologic processes such as glucose metabolism,
and immune system responses, and may have a role in reproduction by influencing
implantation, angiogenesis, and fetal growth. (2, 8, 9)
A larger body of research has focused on leptin and pregnancy complications such as
gestational diabetes (GDM) and preeclampsia (PE). (10, 11) In GDM, placental leptin
appears to be up-regulated. (12) One study reported that preterm pre-eclampsia but not
intrauterine growth restriction (IUGR) was associated with increased placental expression of
leptin. (13) Others have found that amniotic fluid leptin levels (14) were higher in
association with pre-eclampsia, and higher placental leptin levels were linked to both pre-
eclampsia and a greater resistance index of the umbilical artery. (4) These studies, along
with animal models that show higher maternal blood leptin levels following vessel occlusion
(descending aorta and ovarian), (15) all point to greater placental leptin production in
response to decreased placental perfusion.
The majority of studies to date have examined leptin levels at the time of parturition in
mother and/or infant (16), or have measured maternal leptin levels during the first trimester.
(17, 18) In these studies relations between leptin levels and birthweight for gestational age
(BW/GA) were inconsistent, though studies of umbilical cord blood leptin levels and
BW/GA tended to report a positive correlation. (16, 19) Only a few investigators have
evaluated mid-pregnancy leptin levels in association with BW/GA or timing of delivery, and
again results have varied. (7, 20, 21) Studies of leptin in relation to timing of delivery are
especially scarce. Among twin pregnancies, higher leptin levels in amniotic fluid sampled
during the second trimester were associated with lower gestational age at delivery. (22)
Large epidemiological studies have not thoroughly investigated maternal leptin levels while
simultaneously considering BW/GA, timing of delivery and pregnancy complications. Based
on previous studies, we hypothesized that leptin levels would be higher among pregnant
women with increased body mass index (BMI) and/or maternal complications such as
hypertensive disorders and gestational diabetes. Our first aim was to examine associations
between mid-pregnancy maternal serum leptin levels and both BW/GA and timing of
delivery (i.e. term vs. preterm) in models with and without the inclusion of maternal pre-
pregnancy BMI. Our second aim was to re-examine these associations after removing
woman with hypertensive disorders or gestational diabetes.
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Methods
Sample
The study sample came from the Pregnancy Outcomes and Community Health (POUCH)
Study designed to investigate pathways to preterm delivery (PTD) as well as other adverse
pregnancy outcomes. The study received institutional review board approval at Michigan
State University, Michigan Department of Community Health, and nine community
hospitals. Eligibility criteria for the POUCH Study cohort included: 16th–27th week of
pregnancy, maternal serum alpha-fetoprotein (MSAFP) screening, prenatal care at one of 52
clinics in 5 Michigan Communities during September 8, 1998 through June 15, 2004,
singleton pregnancy with no known chromosomal abnormality or birth defect, maternal age
≥ 15 years, no pre-pregnancy diabetes mellitus, and proficiency in English. Women who met
the eligibility criteria and expressed interest in the study constituted the ‘sampling frame’.
Those who had normal MSAFP levels were stratified by race/ethnicity and randomly
sampled into the cohort. In addition, all interested women with unexplained high MSAFP
levels of ≥2 MoM (multiples of the median) were invited to participate because this prenatal
screening biomarker has been consistently linked to risk of PTD. Of the 3038 women
recruited into the cohort, 3019 were followed (99%) through to delivery. Overall 7% of the
cohort had high MSAFP levels compared with the typical 3–5% in the screened population.
In cohort analyses, after sampling weights are applied, women with elevated MSAFP
account for only 3–5% of the cohort, typical of any unselected pregnancy cohort. Thus, the
POUCH Study cohort can be thought of as a survey sample intended to represent the
original sampling frame. At enrollment (16–27 weeks’ gestation) cohort women met with a
study nurse, signed consent forms, completed in-person interviews and self-administered
questionnaires, and had biological samples collected.
In order to conserve resources, some costly data elements (e.g. placental examinations,
medical record abstraction, assays in stored biologic samples) were obtained from only a
sub-sample of POUCH Study participants, referred to as the sub-cohort. The sub-cohort of
1,371 women was assembled by using a random stratified sampling design, sampling from
among the cohort, and again oversampling from certain strata. There were eight sampling
strata defined by race/ethnicity (African American, non-African American), MSAFP levels
(high, normal), and pregnancy outcome (preterm, term). The sub-cohort included 100% of
cohort women who delivered preterm (n=335) and 100% of women who delivered at term
with high MSAFP (n= 165). In the remaining strata of women with normal MSAFP and
term deliveries, the study sampled 72 % of African Americans (n=422) and 23% of non-
African Americans (n=449). The final sample for the current investigation consisted of
1,304 sub-cohort women with complete information on maternal serum leptin levels and
infant BW/GA.
Pregnancy Outcomes
Birthweight data were abstracted from medical records. Gestational age was calculated
based on the last menstrual period unless it disagreed with ultrasound results (majority
conducted at < 22 weeks) by greater than 2 weeks, in which case the ultrasound results were
given preference. The birthweight for gestational age (BW/GA) variable was based on a
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birthweight z-score (BWZ) (23) and consisted of three categories: between the 10th and 90th
percentiles BWZ was considered appropriate-for-gestational age (AGA); ≤10th percentile
BWZ was considered small-for-gestational age (SGA); and ≥90th percentile BMZ was
considered large-for-gestational age (LGA). Timing of delivery was categorized as term
(≥37 weeks’ gestation) and preterm (<37 weeks’ gestation) delivery.
Leptin levels
Leptin was measured in maternal serum collected at enrollment using a commercial RIA kit
purchased from Linco Research, Inc. (HL-81K). The samples were incubated with 125I-
leptin and leptin antibody overnight. The sample was centrifuged after incubating with a
cold precipitating agent. The supernatant was decanted and pellets were counted. The lower
limit of detection was 0.5 μg/L. The intra-assay and inter-assay coefficient of variation were
6.6±0.8% and 5.5±0.9%, respectively.
Pregnancy complications
Hypertension was defined by diastolic blood pressure (DBP)≥90 mm Hg or systolic blood
pressure (SBP) ≥ 140 mm Hg or use of anti-hypertensive medications. If onset of
hypertension was ≤20 weeks’ gestation it was considered chronic (CHTN). Gestational
hypertension (GHTN) was defined as hypertension on 2 different days with onset after 20
weeks’ gestation but before active labor. PE included women with GHTN plus one of the
following as evidence of proteinuria in the absence of genitourinary infection: a) ≥ 300mg
protein/24 hour urine collection or 2+ protein on urine dipstick once after 20 weeks
gestation, b) 1+ protein on two occasions after 20 weeks, or c) proteinuria present before 20
weeks, but levels increased after 20 weeks. When blood pressure data were not completely
recorded, a few PE cases were ascertained based on physician diagnosis in prenatal records.
PE also included diagnosis of PE superimposed over CHTN. GDM was considered present
if a woman met any of the following criteria: failed the glucose tolerance test (GTT) for 1
hour and 3 hours, 1hr GTT> 10.545 mmol/Land GDM diagnosis by physician, 1hr GTT>
10.454 mmol/Land fasting glucose> 5.2725 nmol/L, or no laboratory values but GDM
diagnosis listed in the medical records.
Covariates
Information on maternal characteristics was obtained through questionnaires administered at
enrollment. Maternal age was grouped as <20 years, 20–30 years, and ≥30 years of age. We
categorized self-reported maternal race into four groups: non-Hispanic white, African-
American, Hispanic, and others. Maternal education level was divided as <12 years, 12
years, and ≥12 years. Maternal parity was dichotomized as primiparous and multiparous.
Mother’s Medicaid Insurance enrollment served as a proxy for socio-economic status.
Smoking status at enrollment was modeled as yes or no. Self-reported maternal pre-
pregnancy weight and height were used to calculate body mass index (prepreg-BMI).
Prepreg-BMI and gestational age at blood draw (time of enrollment) both showed a positive
linear trend with leptin levels and were therefore treated as continuous measures in the
analyses.
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Statistical analysis
As noted above, the POUCH cohort and sub-cohort were constructed by probability
sampling from the original sampling frame. Sampling weights were used in all analyses to
produce results that are generalizable to the sampling frame and maintain correct standard
errors for hypothesis testing and confidence intervals. SAS 9.2 SURVEY procedures
incorporated strata and weights into the analyses (SAS Institute, Inc, Cary, NC). Leptin
values were log-transformed to normalize the distribution and included as the dependent
variable in weighted linear regression models with gestational week of blood collection as a
covariate. GMean (GMean) leptin values were obtained from these models and re-
transformed to the original scale for reporting. We first examined GMean leptin levels in
relation to maternal characteristics and pregnancy complications, i.e. hypertensive disorders
and GDM. The linear regression models were constructed with and without maternal pre-
pregnancy BMI as a covariate. Next, we included pregnancy outcomes and found evidence
of an interaction (p-value=0.056) between timing of deliver (term versus preterm) and
BW/GA in relation to leptin levels. As a result we created a 6-level variable for pregnancy
outcome, Term-AGA (referent), Preterm-AGA, Term-SGA, Preterm-SGA, Term-LGA, and
Preterm-LGA and used it in the subsequent analyses. A GMean leptin level was calculated
for each of the six categories, first with gestational week at blood collection as a covariate
and then after adding the covariate pre-pregnancy BMI. Finally, we assessed GMean leptin
levels for the 6-level pregnancy outcome variable after removing women with hypertensive
disorders and GDM to examine the extent to which the associations between pregnancy
outcome and leptin levels were explained by these pregnancy complications.
Results
In the study sample, weighted percentages showed that over two thirds of POUCH Study
participants were under 30 years of age, about one quarter were African-American, greater
than half had ≥12 years of education, and just under a half were enrolled in the Medicaid
Insurance plan (Table 1). As expected, maternal blood leptin levels were highest in obese
women and lowest in underweight women (Table 1). The GMean leptin level in each of the
‘non-normal’ BMI categories was significantly different from that in the group of women
with normal BMI (p<0.001). Only one other maternal characteristic, age at study entry, was
significantly associated with leptin levels. However, maternal age did not remain significant
in multivariable models and did not change the estimates for the effects of other variables in
the models.
Just under 10% of women had some form of hypertensive disorder during the pregnancy
(Table 2). Women with GHTN, PE, and CHTN had higher GMean leptin levels than women
with no hypertension disorders, though with CHTN the difference was not statistically
significant. The GMean leptin level in women with GDM was significantly higher than that
in women without GDM. After including pre-pregnancy maternal BMI as a covariate, the
GMean leptin level remained significantly elevated in association with GHTN but was no
longer associated with PE, CHTN and GDM.
For the 6-level pregnancy outcome variable, the Term-AGA referent category accounted for
approximately 70% of deliveries after applying sampling weights. Women in this group had
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an GMean leptin level of 25.2 μg/L (Table 3). Lower GMean leptin levels were observed in
three categories, women who delivered Preterm-SGA (21.7 μg/L), Preterm-AGA (21.9
μg/L) and Term-SGA (20.3 μg/L). For the Preterm-SGA, the GMeans was not statistically
significantly different from that of the Term-AGA referent, but this may be explained by the
relatively smaller sample size in the Preterm-SGA category (n=20). A significantly higher
GMean leptin level was noted in two other categories, women who delivered Preterm-LGA
(33.6 μg/L) and Term-LGA (29.1 μg/L). After controlling for maternal pre-pregnancy BMI,
differences in the GMean leptin levels were slightly attenuated and the comparison between
the referent Term-AGA and Term-LGA was no longer statistically significant. Further, after
removal of women with any hypertension disorder or with GDM the GMean leptin level was
noticeably attenuated in the Preterm-SGA group, but in all other groups GMeans were
relatively stable and comparisons with the referent group did not change. Similar results
were obtained after removing only women with PE (data not shown).
In other results not detailed here, removal of under-weight mothers from our analysis had
little impact. When we looked within BW/GA categories (AGA, SGA, LGA) and compared
GMean leptin for preterm and term group within the categories, we found a statistically
significant difference in the AGA group only (p=0.003).
Discussion
We found lower maternal leptin levels in blood sampled at mid-pregnancy among women
who delivered SGA infants either term or preterm, though a small sample size limited
inferences about this latter group. In addition, delivery of a preterm AGA infant was
associated with lower maternal leptin levels. These findings persisted after adjusting for
mother’s pre-pregnancy BMI and after removal of women with complications such as
hypertensive disorders or GDM. By contrast the higher maternal leptin levels observed in
mothers of LGA infants was significantly attenuated in models that incorporated pre-
pregnancy BMI, particularly for mothers of term LGA infants.
Overall, findings from studies of maternal leptin levels and SGA infants have been
inconsistent. Some have reported no significant association; (18, 19, 21, 24) one of the
reasons for this observation could be the small number of SGA infants relative to our sample
size. Other researchers have observed higher maternal leptin levels in association with an
SGA infant. (8, 20, 25) Most of these latter studies examined only term births and maternal
leptin levels were measured close to or at the time of delivery. Often it was not clear
whether women with pregnancy complications were excluded, and sample sizes tended to be
small. Results from two studies were similar to our finding of lower leptin levels in mothers
who delivered SGA infants, preterm or term. One of the studies gathered repeated measures
of maternal leptin levels across pregnancy and excluded women with pre-eclampsia. (7) The
other measured maternal leptin levels during the first trimester. (17)
In uncomplicated pregnancies maternal leptin levels increase by 2–3 fold over the course of
pregnancy. (6) The placenta produces leptin (26) which is thought to support placental
growth and create a maternal leptin resistance environment so that mothers maintain a
positive energy state. (1) During pregnancy the free leptin form remains constant whereas
Shroff et al. Page 6
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2014 April 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the bound form of leptin is increased. (27) This is in contrast to the condition of obesity
during the non-pregnant state in which free leptin increases and levels of soluble leptin
receptor remain constant. (28) The biological pathways linking maternal blood leptin levels
and fetal growth need further investigation. One hypothesis is that the combination of a
small or compromised placenta and poor fetal growth is accompanied by lower levels of
leptin in maternal blood. In the unique situation of preeclampsia, placentas compensate and
put out excess leptin resulting in higher maternal blood levels, but fetal growth may still be
impaired. (7) A decrease in maternal vascular expansion (less hemodilution) associated with
preeclampsia (29) might also contribute to observing higher maternal blood leptin levels.
After adjusting for pre-pregnancy BMI we found that maternal leptin levels remained
elevated in women with PE and in women with GHTN, the group with the highest leptin
levels. In pregnancies complicated by hypertensive disorders, total placental production of
leptin may not be altered but less is directed to the fetus and therefore a larger percentage
enters the maternal circulation.
We also found lower mid-pregnancy leptin levels in mothers who delivered preterm AGA
infants. While this may reflect underlying pathology related to early delivery, there are other
possible explanations. The BW/GA cut-points that defined AGA were obtained by using
percentiles from a livebirth referent population. (23) Given the same GA, preterm livebirths
are, on average, smaller than fetuses who are still in-utero. (30) Thus among preterm the
lower bounds of the AGA might include some who are SGA but classified as AGA. Based
on these explanations it may be that maternal leptin levels are primarily related to BW/GA
and there is minimal additional relation to prematurity.
On the other extreme of BW/GA, two studies examined maternal leptin levels in relation to
delivery of an LGA infant, and both found no significant association after adjusting for
maternal pre-pregnancy weight. (20, 31) One measured leptin levels at delivery with a
sample size of only 17 women delivering LGA infants. (31) The other categorized leptin
levels and therefore had limited statistical power. (20) The association we observed between
higher maternal leptin levels and delivery of an LGA infant was attenuated by inclusion of
maternal pre-pregnancy BMI, but still significant for the preterm LGA. Blood leptin level is
closely linked to BMI and strongly correlated with body fat in non-pregnant populations.
(32) But the correlation is reduced in pregnant women, most likely due to the placental
contribution of leptin to the maternal circulation. We found a moderate to strong correlation
(r=0.62) between maternal leptin level and pre-pregnancy BMI in our data which agrees
with that reported by other studies of pregnant women. (7) In non-pregnant populations high
blood leptin levels are associated with insulin-resistance (33), and this may be one
mechanism that links leptin levels and delivery of larger babies. (20) After removing women
with GDM or hypertensive disorders and adjusting for maternal prepreg-BMI, the persistent
association between higher maternal leptin levels and preterm LGA in our data may mark a
group with underlying elements of the metabolic syndrome without progression to GDM.
To our knowledge, this is the largest prospective study of relations between mid-pregnancy
leptin levels and adverse pregnancy outcomes including prematurity. The large sample size
allowed us to detect an interaction between BW/GA and timing of delivery and to assess
leptin levels in groups defined by these two pregnancy outcomes. In addition, the POUCH
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Study cohort included a socioeconomically diverse group of women who were
representative of those delivering in the study communities, thereby enhancing the potential
for generalizability. Careful medical record abstraction enabled the identification of
pregnancy complications such as hypertensive disorders and GDM, to better understand
their influence in leptin-pregnancy outcome associations.
Our reliance on a single measure of maternal leptin levels in pregnancy was a clear
limitation. If maternal blood leptin levels reflect placental leptin production, as suggested by
others (1, 7, 25), monitoring leptin across pregnancy might provide additional clues about
placental function and its relation to fetal growth. A dilemma for any study of leptin levels
in pregnancy is the problem of maternal anthropometrics. As a means of adjusting for
adiposity, BMI is imperfect and there is an opportunity for residual confounding.
Conversely, leptin derived from maternal adipocytes, or maternal weight-related leptin
resistance may be in the pathway to pregnancy outcome. Leptin produced by the placenta
will be diluted in maternal circulation according to maternal size, and thus adjustment for
maternal BMI would be indicated. Because of these challenges, we presented results with
and without maternal prepreg-BMI in the models, but all these caveats must be considered.
In addition, it is likely that leptin is part of a larger network of biomarkers which together
may mediate or mark pregnancy outcomes. Therefore one must be cautious in assigning a
causal role to any single biomarker.
In conclusion, our study findings suggest that a careful evaluation of maternal leptin levels
and pregnancy outcome should include both measures of infant size and timing of delivery,
to understand the implications of potential interactions. Relations between leptin levels and
pregnancy outcome are not fully explained by maternal BMI or by complications often
associated with high BMI such as GDM and hypertensive disorders. These results point to a
potentially intriguing role of mid-pregnancy placental leptin as marker and/or mediator in
fetal growth. Our future direction will include an examination of maternal leptin levels in
conjunction with placental pathologic findings within the POUCH Study.
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Table 1
Weighted frequencies of maternal characteristics and their associated geometric means (GMeans) leptin levels
(n=1,304)
Maternal characteristics N Wt % GMeansa (μg/L) 95% CI
Age
 <20 (Ref) 229 14.7 23.2 [21.4, 25.2]
 20–30 737 57.1 25.8 [24.6, 27.0] **
 >=30 338 28.2 24.0 [22.5, 25.7]
Race
 Non-Hispanic white (Ref) 671 65.7 25.2 [24.1, 26.3]
 African American 535 24.6 24.6 [23.3, 25.9]
 Hispanic 58 5.2 25.8 [21.8, 30.4]
 Others 40 4.4 22.5 [18.4, 27.4]
Education
 <12 years (Ref) 297 19 24.1 [22.3, 26.0]
 12 years 370 27.2 26.6 [24.9, 28.4]
 >12 years 637 53.8 24.4 [23.3, 25.6]
Parity
 Primiparous (Ref) 546 41.3 24.8 [23.4, 26.2]
 Multiparous 757 58.7 25.0 [23.9, 26.1]
Smoking
 No (Ref) 938 72.6 25.1 [24.1, 26.1]
 Yes 366 27.4 24.4 [22.9, 26.1]
Medicaid status
 No (Ref) 565 50.9 24.6 [23.4, 25.9]
 Yes 737 49.1 25.2 [24.0, 26.5]
Gestational age Enrollment (weeks)
 15–<20 (Ref) 213 15.7 24.0 [21.9, 26.4]
 20–<25 915 71.1 24.9 [23.9, 25.9]
 25–<28 176 13.2 26.2 [23.8, 28.7]
Pre-pregnancy BMI
 Underweight (<18.5) 61 3.8 12.4 [10.6, 14.4] ****
 Normal (18.5–24.9) (Ref) 585 46.9 19.2 [18.3, 20.1]
 Overweight (25.0–29.9) 289 22.9 29.2 [27.7, 30.7] ****
 Obese (>=30) 369 26.3 38.4 [36.6, 40.2] ****
aAdjusted for gestational week at blood collection
**p-value < 0.05;
****p-value <0.0001
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